Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs.

LeBlanc AK, Naik S, Galyon GD, Jenks N, Steele M, Peng KW, Federspiel MJ, Donnell R, Russell SJ.

Hum Gene Ther Clin Dev. 2013 Dec;24(4):174-81. doi: 10.1089/humc.2013.165.

2.

Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV.

Velazquez-Salinas L, Naik S, Pauszek SJ, Peng KW, Russell SJ, Rodriguez LL.

Hum Gene Ther Clin Dev. 2017 Jun;28(2):108-115. doi: 10.1089/humc.2017.015.

PMID:
28514874
3.

Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS.

Zhang L, Steele MB, Jenks N, Grell J, Suksanpaisan L, Naik S, Federspiel MJ, Lacy MQ, Russell SJ, Peng KW.

Hum Gene Ther Clin Dev. 2016 Sep;27(3):111-22. doi: 10.1089/humc.2016.061.

4.

Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.

Naik S, Nace R, Barber GN, Russell SJ.

Cancer Gene Ther. 2012 Jul;19(7):443-50. doi: 10.1038/cgt.2012.14. Epub 2012 Apr 20.

5.

Comparative oncology evaluation of intravenous recombinant oncolytic Vesicular Stomatitis Virus therapy in spontaneous canine cancer.

Naik S, Galyon GD, Jenks NJ, Steele MB, Miller AC, Allstadt SD, Suksanpaisan L, Peng KW, Federspiel MJ, Russell SJ, LeBlanc AK.

Mol Cancer Ther. 2017 Nov 20. pii: molcanther.0432.2017. doi: 10.1158/1535-7163.MCT-17-0432. [Epub ahead of print]

PMID:
29158470
6.

rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy.

Wu L, Huang TG, Meseck M, Altomonte J, Ebert O, Shinozaki K, García-Sastre A, Fallon J, Mandeli J, Woo SL.

Hum Gene Ther. 2008 Jun;19(6):635-47. doi: 10.1089/hum.2007.163.

7.

The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.

Rommelfanger DM, Compte M, Diaz RM, Ilett E, Alvarez-Vallina L, Thompson JM, Kottke TJ, Melcher A, Vile RG.

Mol Ther. 2013 Feb;21(2):348-57. doi: 10.1038/mt.2012.204. Epub 2012 Sep 25. Erratum in: Mol Ther. 2013 Apr;21(4):913. Grau, Marta C [corrected to Compte, Marta].

8.

Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia.

Betancourt D, Ramos JC, Barber GN.

J Virol. 2015 Dec;89(23):11786-800. doi: 10.1128/JVI.01356-15. Epub 2015 Sep 16.

9.

Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.

Liu YP, Steele MB, Suksanpaisan L, Federspiel MJ, Russell SJ, Peng KW, Bakkum-Gamez JN.

Gynecol Oncol. 2014 Jan;132(1):194-202. doi: 10.1016/j.ygyno.2013.11.010. Epub 2013 Nov 15.

10.

Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.

Yu N, Puckett S, Antinozzi PA, Cramer SD, Lyles DS.

J Virol. 2015 May;89(10):5250-63. doi: 10.1128/JVI.00257-15. Epub 2015 Mar 4.

11.

Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer.

Hastie E, Grdzelishvili VZ.

J Gen Virol. 2012 Dec;93(Pt 12):2529-45. doi: 10.1099/vir.0.046672-0. Epub 2012 Oct 10. Review.

12.

Oncolytic vesicular stomatitis virus administered by isolated limb perfusion suppresses osteosarcoma growth.

Kubo T, Shimose S, Matsuo T, Fujimori J, Sakaguchi T, Yamaki M, Shinozaki K, Woo SL, Ochi M.

J Orthop Res. 2011 May;29(5):795-800. doi: 10.1002/jor.21307. Epub 2010 Dec 17.

13.

Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.

Galivo F, Diaz RM, Wongthida P, Thompson J, Kottke T, Barber G, Melcher A, Vile R.

Gene Ther. 2010 Feb;17(2):158-70. doi: 10.1038/gt.2009.161. Epub 2009 Dec 17.

15.

Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.

Patel MR, Jacobson BA, Ji Y, Drees J, Tang S, Xiong K, Wang H, Prigge JE, Dash AS, Kratzke AK, Mesev E, Etchison R, Federspiel MJ, Russell SJ, Kratzke RA.

Oncotarget. 2015 Oct 20;6(32):33165-77. doi: 10.18632/oncotarget.5320.

16.

Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.

Shin EJ, Wanna GB, Choi B, Aguila D 3rd, Ebert O, Genden EM, Woo SL.

Laryngoscope. 2007 Feb;117(2):210-4.

PMID:
17204993
17.

Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.

Wollmann G, Drokhlyansky E, Davis JN, Cepko C, van den Pol AN.

J Virol. 2015 Jul;89(13):6711-24. doi: 10.1128/JVI.00709-15. Epub 2015 Apr 15.

18.

Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates.

Jenks N, Myers R, Greiner SM, Thompson J, Mader EK, Greenslade A, Griesmann GE, Federspiel MJ, Rakela J, Borad MJ, Vile RG, Barber GN, Meier TR, Blanco MC, Carlson SK, Russell SJ, Peng KW.

Hum Gene Ther. 2010 Apr;21(4):451-62. doi: 10.1089/hum.2009.111.

19.

Vesiculovirus neutralization by natural IgM and complement.

Tesfay MZ, Ammayappan A, Federspiel MJ, Barber GN, Stojdl D, Peng KW, Russell SJ.

J Virol. 2014 Jun;88(11):6148-57. doi: 10.1128/JVI.00074-14. Epub 2014 Mar 19. Erratum in: J Virol. 2015 Feb;89(3):1945-6.

20.

Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.

Shen W, Patnaik MM, Ruiz A, Russell SJ, Peng KW.

Blood. 2016 Mar 17;127(11):1449-58. doi: 10.1182/blood-2015-06-652503. Epub 2015 Dec 28.

Supplemental Content

Support Center